TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27160363
Drug: Etodolac (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac (300 mg 3 times a day for 3 days)
Study: 25245386
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (calcium channel blocker-based or β-blocker-based)
Study: 22673596
Drug: GPC 1000
Normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPC 1000 mg
Study: 20493274
Drug: SE36/AHG (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: SE36/AHG (50 and 100 microg doses)
Study: 18822979
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine group
Study: 15580060
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (IMT) at 60% of individual sustained maximal inspiratory pressure (SMIP) for 10 weeks, three times weekly.
Study: 15580060
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group exercised at 15% of SMIP for 10 weeks, three times weekly.
Study: 11721719
Drug: GP IIb/IIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP IIb/IIIa inhibitors, heparin according to TIMI 14 trial, and aspirin
Study: 11721719
Drug: Placebo, rt-PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, rt-PA 100 mg, standard heparin treatment, and aspirin
Study: 11765119
Drug: GP IIb/IIIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP IIb/IIIa inhibitors
Study: 7894208
Drug: D-Tryptophan-6 luteinizing
Normalized name: (6-D-Tryptophan)luteinizing hormone-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-Tryptophan-6 luteinizing hormone releasing hormone (D-Trp-6-LH-RH)
Study: 30012107
Drug: eGFR 30-59
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR 30-59 ml/min/1.73 m2 (mild to moderate RI)
Study: 30012107
Drug: eGFR <30
Approvals — FDA: no, EMA: no, PMDA: no
Description: eGFR <30 ml/min/1.73 m2 (severe RI)
Study: 25054399
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic alone (1.5 mL of 1% preservative-free lidocaine)
Study: 20354688
Drug: Paroxetine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 50 mg
Study: 30868305
Drug: Spreader flaps
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spreader flaps used in combination with spreader grafts (Group 1)
Study: 12831522
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg/day for 5 days)
Study: 10720024
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone gel applied at four sites (left and right arms/shoulders and left and right abdomen)
Study: 3937968
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Mitomycin treatment)
Study: 3937968
Drug: Mitomycin treatment
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin treatment
Study: 25875940
Drug: Oral levodopa-carbidopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral levodopa-carbidopa (LC-oral)
Study: 23648698
Drug: Adrenalectomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenalectomy and Medical therapy (PA patients)
Study: 19106196
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of BMPC
Study: 17404349
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous abdominal injections twice daily for 16 weeks)
Study: 8822986
Drug: Enalaprilat (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (1 mg)
Study: 1444500
Drug: 2% topical
Normalized name: A/T/S 2% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% topical minoxidil applied three times daily
Study: 1444500
Drug: Prednisone (6-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (6-week taper)
Study: 27688166
Drug: Bisphosphonate-coated implants
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate-coated implants
Study: 27688166
Drug: Control (uncoated)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (uncoated) implants
Study: 27688166
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both implant types
Study: 22442826
Drug: Vildagliptin 10
Normalized name: vildagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 10 mg
Study: 22442826
Drug: Vildagliptin 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 25 mg
Study: 19736246
Drug: 9 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g/day MCI-196
Study: 19736246
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of MCI-196
Study: 18932258
Drug: ABT-510 10
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-510 10 mg twice daily
Study: 18932258
Drug: ABT-510 25
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-510 25 mg twice daily
Study: 18932258
Drug: ABT-510 50
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-510 50 mg twice daily
Study: 7841965
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment alone
Study: 16187776
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy after 6 months of drug treatment alone
Study: 14507272
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of oral calcium carbonate
Study: 14507272
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of oral calcium carbonate
Study: 14507272
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of open-label calcium carbonate
Study: 8777827
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet with 13.7 g of urea added (LP-U2)
Study: 26872548
Drug: High-dose casein
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose casein (HP)
Study: 26872548
Drug: Low-dose casein
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose casein (LP)
Study: 12213142
Drug: Aspirin therapy
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin therapy (low-risk/low-benefit)
Study: 7609571
Drug: Sodium loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium loading (1 ml/kg of 10% NaCl infused for 15 minutes)
Study: 57520
Drug: WRL 105
Approvals — FDA: no, EMA: no, PMDA: no
Description: WRL 105 strain live influenza vaccine
Study: 21593114
Drug: teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: teriparatide (20 μg sc once daily)
Study: 21593114
Drug: alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: alendronate (70 mg once weekly)
Study: 16333632
Drug: Both Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Enoxaparin and Heparin
Study: 11084176
Drug: Intranasal 17
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 17 beta‐E2, 300 microg daily
Study: 9333058
Drug: Single-dose chlorproguanil-dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose chlorproguanil-dapsone
Study: 8437527
Drug: SBT/AMP 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SBT/AMP 1 g/2 g t.i.d. (n=35 clinically evaluable)
Study: 8437527
Drug: CXM 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXM 1.5 g t.i.d. (n=35 clinically evaluable)
Study: 2875812
Drug: Nadolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (40 mg bid)
Study: 29635061
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg phenylephrine HCl combined with 650 mg acetaminophen, fasted
Study: 29635061
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg phenylephrine HCl, fed
Study: 26616001
Drug: Ketorolac nasal
Normalized name: ketorolac Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac nasal spray 31.5 mg
Study: 26616001
Drug: Oxycodone/ibuprofen 5/400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/ibuprofen 5/400 mg
Study: 26616001
Drug: Oxycodone/APAP 5/325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone/APAP 5/325 mg
Study: 26616001
Drug: Ketorolac nasal
Normalized name: ketorolac Nasal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac nasal spray
Study: 26616001
Drug: Tramadol HCl/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol HCl/APAP 75/650 mg
Study: 26616001
Drug: Tramadol HCl/APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol HCl/APAP 37.5/325 mg
Study: 24585406
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2) and carboplatin (AUC=5) followed by gefitinib (250 mg/day) for 6 months
Study: 24585406
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2) and carboplatin (AUC=5) alone
Study: 23109900
Drug: Genotypes of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotypes of ACAT‐1 CC; ACAT‐1 AA and CC
Study: 8669221
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of sufentanil of 15 micrograms/h
Study: 8669221
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of sufentanil of 30 micrograms/h
Study: 2148735
Drug: Chandonium iodide
Normalized name: Echothiophate Iodide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chandonium iodide 0.25 mg/kg
Study: 29158123
Drug: Necitumumab continuation
Normalized name: Necitumumab
DrugBank: Necitumumab (DB09559)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Necitumumab continuation therapy
Study: 28404091
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (300 mg)
Study: 17493710
Drug: Flu vaccine
Normalized name: flu vaccine 2012 (18-64yrs)/PF 27 mcg/0.1 mL INTRADERM SYRINGE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu vaccine plus 10 microg IMP321
Study: 17493710
Drug: Flu vaccine
Normalized name: flu vaccine 2012 (18-64yrs)/PF 27 mcg/0.1 mL INTRADERM SYRINGE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu vaccine plus 30 microg IMP321
Study: 17493710
Drug: Flu vaccine
Normalized name: flu vaccine 2012 (18-64yrs)/PF 27 mcg/0.1 mL INTRADERM SYRINGE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu vaccine plus 100 microg IMP321
Study: 17493710
Drug: Flu vaccine
Normalized name: flu vaccine 2012 (18-64yrs)/PF 27 mcg/0.1 mL INTRADERM SYRINGE (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu vaccine plus saline control
Study: 16179039
Drug: Total Intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Intravenous Anaesthesia (TIVA, n = 19)
Study: 25555797
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl
Study: 1713985
Drug: benazepril 10
Normalized name: benazepril 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: benazepril 10 mg twice daily (b.i.d.) for 2 weeks
Study: 11913804
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (30 mg kg(‐1) bolus followed by 0.5 g h(‐1) infusion for 20 hours)
Study: 11913804
Drug: Isotonic sodium
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic sodium chloride solution (same volume as magnesium)
Study: 2031797
Drug: iohexol 300
Normalized name: IOHEXOL 300MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 300 mg I/ml (690 mosm/kg H2O)
Study: 31608551
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg pregabalin
Study: 31982359
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg pregabalin
Study: 31163544
Drug: Compound or
Normalized name: Soma Compound Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound or multi-drug resistant bacteria group
Study: 31163544
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups compared to compound or multi-drug resistant bacteria group
Study: 9097895
Drug: Testosterone (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (50, 100, and 200 mg)
Study: 8474402
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g fish oil (3.15 g n-3 fatty acids per day)
Study: 8474402
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g olive oil
Study: 31356713
Drug: CBT +
Normalized name: Cannabidiol
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBT + medication
Study: 31356713
Drug: Treatment response
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment response and remission
Study: 29231499
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (acupuncture plus ginger moxibustion at Heding EX-LE 2)
Study: 15247013
Drug: Vitamin E,
Normalized name: GRx Vitamin E, topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin E, 300 mg/day
Study: 15247013
Drug: Multivitamin, two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin, two tablets t.i.d.
Study: 15247013
Drug: Immun‐Age 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immun‐Age 6 g/day nocte
Study: 8452189
Drug: Single-dose fleroxacin
Normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose fleroxacin (400 mg)
Study: 8452189
Drug: 7-day fleroxacin
Normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day fleroxacin (200 mg once a day)
Study: 31740197
Drug: EPA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (1 g per day for 6 days)
Study: 31740197
Drug: DHA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (1 g per day for 6 days)
Study: 27635620
Drug: Preradiation chemotherapy
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preradiation chemotherapy with cisplatin, etoposide, cyclophosphamide, and vincristine followed by craniospinal radiation (CSI)
Study: 14667998
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of oestradiol
Study: 10923059
Drug: Critical tests
Normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Critical tests administered at the beginning and end of the session
Study: 10923059
Drug: Critical tests
Normalized name: Critic-Aid Clear
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Critical tests administered only once, at the end of the session
Study: 20598123
Drug: Supervised implementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised implementation of the oral health care guideline and daily oral health care protocol
Study: 20840223
Drug: Non-supervised implementation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-supervised implementation of the oral health care guideline
Study: 17236474
Drug: Assistive technology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assistive technology supplement to the School Function Assessment
Study: 15244185
Drug: 150 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/m2 irinotecan once a week for four weeks followed by a two-week drug-free interval
Study: 11220295
Drug: Rosiglitazone 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 1.0 mg b.i.d.
Study: 11220295
Drug: Rosiglitazone 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 2.0 mg b.i.d.
Study: 2861523
Drug: J5 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: J5 antibody recipients
Study: 30515431
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg on day 1 and then 5 mg/kg once daily for 4 days)
Study: 23018908
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (100/25 μg)
Study: 21926181
Drug: Anthocyanins (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanins (320 mg) in short-term study
Study: 21926181
Drug: Anthocyanins (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanins (320 mg/day) in long-term study
Study: 21926181
Drug: Anthocyanins with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthocyanins with NO-cGMP inhibitors
Study: 12911777
Drug: Oral challenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral challenges with peanut
Study: 12911777
Drug: Oral challenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral challenges with milk
Study: 12911777
Drug: Oral challenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral challenges with peanut oil
Study: 3281702
Drug: Preference for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference for treatment
Study: 22872218
Drug: Bisphosphonate (17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate (17.5 mg weekly oral risedronate)
Study: 12791113
Drug: 0.7 ml.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 ml.kg-1 of 0.175% bupivacaine with 1 : 200 000 epinephrine
Study: 12791113
Drug: 1.0 ml.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml.kg-1 of 0.175% bupivacaine with 1 : 200 000 epinephrine
Study: 12791113
Drug: 1.3 ml.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 ml.kg-1 of 0.175% bupivacaine with 1 : 200 000 epinephrine
Study: 12791113
Drug: 0.7 ml.kg-1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 ml.kg-1, 1.0 ml.kg-1, 1.3 ml.kg-1 of 0.175% bupivacaine with 1 : 200 000 epinephrine
Study: 1398281
Drug: Calcium Heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Heparin (5000 IU subcutaneously twice daily beginning 2 hours before surgery)
Study: 6758747
Drug: Calcium Heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Heparin
Study: 3912189
Drug: Vindeburnol 30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindeburnol 30, 60 or 90 mg/d
Study: 27888448
Drug: Topical clobetasol
Normalized name: clobetasol Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical clobetasol propionate 0.05% cream under occlusion with silicone dressing
Study: 16799234
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg edaravone intravenously just before reperfusion
Study: 11125896
Drug: Health worker
Normalized name: Apis cerana worker secretion preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health worker training and STD syndrome packets (containing recommended drugs, condoms, partner notification cards, and information leaflets)
Study: 3731680
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution placebo
Study: 31908513
Drug: Wash+lotion
Normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wash+lotion
Study: 31908513
Drug: Water+lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water+lotion
Study: 30152116
Drug: Dual induction
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual induction therapy (rATG combined with either daclizumab or alemtuzumab) with planned early corticosteroid withdrawal
Study: 15580349
Drug: Alendronate (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (70 mg/week)
Study: 19216650
Drug: Nicardipine prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine prolonged-release implants (NPRIs)
Study: 1742754
Drug: Saline (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (control group) administered via i.v. infusion starting 30 min before APO administration.
Study: 28902040
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg administered twice daily for 12 weeks
Study: 19036752
Drug: Once-daily lamivudine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily lamivudine, tenofovirDF and nevirapine (Group 2)
Study: 19036752
Drug: Zidovudine/lamivudine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine/lamivudine and nevirapine twice daily (Group 1)
Study: 17156512
Drug: Standard pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pain treatment
Study: 16013662
Drug: 0.25 microg
Normalized name: calcitriol 0.25 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 microg kg(‐1) remifentanil + propofol 2 mg kg(‐1)
Study: 16013662
Drug: 0.50 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 microg kg(‐1) remifentanil + propofol 2 mg kg(‐1)
Study: 1921784
Drug: Sublingual apomorphine
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual apomorphine (10-30 mg)
Study: 1921784
Drug: Subcutaneous apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous apomorphine (1-3 mg)
Study: 1921784
Drug: Oral levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral levodopa
Study: 6405444
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg IV naloxone
Study: 19852288
Drug: Gulling Pa'an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gulling Pa'an Capsule (GPC) in group A
Study: 19852288
Drug: Gulling Pa'an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gulling Pa'an Capsule + Levodopa in group C
Study: 19852288
Drug: Gulling Pa'an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gulling Pa'an Capsule + Levodopa in group E